<?xml version='1.0' encoding='utf-8'?>
<document id="16192110"><sentence text="Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes."><entity charOffset="75-84" id="DDI-PubMed.16192110.s1.e0" text="valsartan" /><entity charOffset="108-122" id="DDI-PubMed.16192110.s1.e1" text="angiotensin II" /><pair ddi="false" e1="DDI-PubMed.16192110.s1.e0" e2="DDI-PubMed.16192110.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16192110.s1.e0" e2="DDI-PubMed.16192110.s1.e1" /></sentence><sentence text="Valsartan is known to be excreted largely as unchanged compound and is minimally metabolized in man"><entity charOffset="0-9" id="DDI-PubMed.16192110.s2.e0" text="Valsartan" /></sentence><sentence text=" Although the only notable metabolite is 4-hydroxyvaleryl metabolite (4-OH valsartan), the responsible enzyme has not been clarified at present"><entity charOffset="41-57" id="DDI-PubMed.16192110.s3.e0" text="4-hydroxyvaleryl" /></sentence><sentence text=" The current in vitro studies were conducted to identify the cytochrome P450 (CYP) enzymes involved in the formation of 4-OH valsartan"><entity charOffset="120-134" id="DDI-PubMed.16192110.s4.e0" text="4-OH valsartan" /></sentence><sentence text=" Valsartan was metabolized to 4-OH valsartan by human liver microsomes and the Eadie-Hofstee plots were linear"><entity charOffset="1-10" id="DDI-PubMed.16192110.s5.e0" text="Valsartan" /><entity charOffset="30-44" id="DDI-PubMed.16192110.s5.e1" text="4-OH valsartan" /><pair ddi="false" e1="DDI-PubMed.16192110.s5.e0" e2="DDI-PubMed.16192110.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16192110.s5.e0" e2="DDI-PubMed.16192110.s5.e1" /></sentence><sentence text=" The apparent Km and Vmax values for the formation of 4-OH valsartan were 41"><entity charOffset="54-68" id="DDI-PubMed.16192110.s6.e0" text="4-OH valsartan" /></sentence><sentence text="9-55" /><sentence text="8 microM and 27" /><sentence text="2-216" /><sentence text="9 pmol min(-1) mg(-1) protein, respectively" /><sentence text=" There was good correlation between the formation rates of 4-OH valsartan and diclofenac 4'-hydroxylase activities (representative CYP2C9 activity) of 11 individual microsomes (r = 0"><entity charOffset="59-73" id="DDI-PubMed.16192110.s11.e0" text="4-OH valsartan" /><entity charOffset="78-88" id="DDI-PubMed.16192110.s11.e1" text="diclofenac" /><pair ddi="false" e1="DDI-PubMed.16192110.s11.e0" e2="DDI-PubMed.16192110.s11.e0" /><pair ddi="false" e1="DDI-PubMed.16192110.s11.e0" e2="DDI-PubMed.16192110.s11.e1" /></sentence><sentence text="889)" /><sentence text=" No good correlation was observed between any of the other CYP enzyme marker activities (CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A)" /><sentence text=" Among the recombinant CYP enzymes examined (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5 and 4A11), CYP2C9 notably catalysed 4-hydroxylation of valsartan"><entity charOffset="155-164" id="DDI-PubMed.16192110.s14.e0" text="valsartan" /></sentence><sentence text=" For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan"><entity charOffset="57-68" id="DDI-PubMed.16192110.s15.e0" text="furafylline" /><entity charOffset="70-80" id="DDI-PubMed.16192110.s15.e1" text="diclofenac" /><entity charOffset="82-98" id="DDI-PubMed.16192110.s15.e2" text="S(+)-mephenytoin" /><entity charOffset="100-109" id="DDI-PubMed.16192110.s15.e3" text="quinidine" /><entity charOffset="114-128" id="DDI-PubMed.16192110.s15.e4" text="troleandomycin" /><entity charOffset="136-146" id="DDI-PubMed.16192110.s15.e5" text="diclofenac" /><entity charOffset="174-188" id="DDI-PubMed.16192110.s15.e6" text="4-OH valsartan" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e0" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e1" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e2" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e3" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e4" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e5" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e0" e2="DDI-PubMed.16192110.s15.e6" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e1" e2="DDI-PubMed.16192110.s15.e1" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e1" e2="DDI-PubMed.16192110.s15.e2" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e1" e2="DDI-PubMed.16192110.s15.e3" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e1" e2="DDI-PubMed.16192110.s15.e4" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e1" e2="DDI-PubMed.16192110.s15.e5" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e1" e2="DDI-PubMed.16192110.s15.e6" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e2" e2="DDI-PubMed.16192110.s15.e2" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e2" e2="DDI-PubMed.16192110.s15.e3" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e2" e2="DDI-PubMed.16192110.s15.e4" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e2" e2="DDI-PubMed.16192110.s15.e5" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e2" e2="DDI-PubMed.16192110.s15.e6" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e3" e2="DDI-PubMed.16192110.s15.e3" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e3" e2="DDI-PubMed.16192110.s15.e4" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e3" e2="DDI-PubMed.16192110.s15.e5" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e3" e2="DDI-PubMed.16192110.s15.e6" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e4" e2="DDI-PubMed.16192110.s15.e4" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e4" e2="DDI-PubMed.16192110.s15.e5" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e4" e2="DDI-PubMed.16192110.s15.e6" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e5" e2="DDI-PubMed.16192110.s15.e5" /><pair ddi="false" e1="DDI-PubMed.16192110.s15.e5" e2="DDI-PubMed.16192110.s15.e6" /></sentence><sentence text=" These results showed that CYP2C9 is the only form responsible for 4-hydroxylation of valsartan in human liver microsomes"><entity charOffset="86-95" id="DDI-PubMed.16192110.s16.e0" text="valsartan" /></sentence><sentence text=" Although CYP2C9 is involved in valsartan metabolism, CYP-mediated drug-drug interaction between valsartan and other co-administered drugs would be negligible"><entity charOffset="32-41" id="DDI-PubMed.16192110.s17.e0" text="valsartan" /><entity charOffset="97-106" id="DDI-PubMed.16192110.s17.e1" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.16192110.s17.e0" e2="DDI-PubMed.16192110.s17.e0" /><pair ddi="false" e1="DDI-PubMed.16192110.s17.e0" e2="DDI-PubMed.16192110.s17.e1" /></sentence><sentence text="" /></document>